Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
Sosne G, Ousler GW. Clinical Ophthalmology 2015;9:877-884.
What it found
Neither primary endpoint (ocular discomfort and inferior corneal staining at day 29) differed from placebo. Some secondary measures, such as discomfort during the day-28 challenge and central corneal staining, were better with Tβ4. No adverse events were reported.
Limitations
Missed its primary endpoints; positive findings are secondary. Single centre. Full protein as eye drops.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.